Mental healthcare biotech company advancing psilocybin therapy COMPASS Pathways plc (NASDAQ: CMPS) reported its financial results for the first quarter 2023 ended March 31, 2023 and updated on recent business and clinical progresses.
Cash and cash equivalents totaled $117.1 million as of March 31, 2023 compared to $143.2 million as of 31 Dec. 2022.
Net loss was $24.2 million ($0.57 loss per share) compared to $21.2 million ($0.50 loss per share) in the first quarter of 2022.
R&D expenses were $19.0 million compared to $15.4 million in the same period in 2022.
G&A expenses were $12.8 million compared to $10.1 million in the same period …